公开(公告)号：US07875450B2

公开(公告)日：2011-01-25

申请号：US12050892

申请日：2008-03-18

Applicant: John T. Schiller ,  Bryce Chackerian ,  Douglas R. Lowy

Inventor： John T. Schiller ,  Bryce Chackerian ,  Douglas R. Lowy

IPC: A61K31/00 ,  C12P21/01

CPC classification number: C12N7/00 ,  A61K38/00 ,  A61K39/00 ,  A61K47/6901 ,  A61K2039/5258 ,  C07K14/005 ,  C07K14/525 ,  C07K14/7158 ,  C07K16/084 ,  C07K16/241 ,  C07K16/2866 ,  C07K17/00 ,  C07K2317/34 ,  C07K2319/20 ,  C07K2319/40 ,  C07K2319/74 ,  C12N2710/14143 ,  C12N2710/20022 ,  C12N2710/20023 ,  C12N2710/22022 ,  C12N2710/22023

Abstract: The invention described herein relates to compositions and methods for stimulating immune responses in vivo against a tolerogen. Novel biotechnological tools, pharmaceuticals, therapeutics and prophylactics, which concern chimeric or conjugated virus-like particles, and methods of use of the foregoing are provided for the study of B cell tolerance and the treatment or prevention of human diseases, which involve the onset of B cell tolerance, such as chronic viral infection, chronic inflammatory disease, and neoplasia.

Abstract translation: 本文描述的本发明涉及用于在体内刺激针对耐受原的免疫应答的组合物和方法。 提供了关于嵌合或共轭病毒样颗粒的新型生物技术工具，药物，治疗和预防措施以及前述用途的方法用于研究B细胞耐受性和治疗或预防人类疾病，其涉及 B细胞耐受，如慢性病毒感染，慢性炎性疾病和瘤形成。

公开(公告)号：US20060210587A1

公开(公告)日：2006-09-21

申请号：US11415611

申请日：2006-05-01

Applicant: John Schiller ,  Bryce Chackerian ,  Douglas Lowy

Inventor： John Schiller ,  Bryce Chackerian ,  Douglas Lowy

IPC: C12Q1/68 ,  A61K39/12

CPC classification number: C12N7/00 ,  A61K38/00 ,  A61K39/00 ,  A61K47/6901 ,  A61K2039/5258 ,  C07K14/005 ,  C07K14/525 ,  C07K14/7158 ,  C07K16/084 ,  C07K16/241 ,  C07K16/2866 ,  C07K17/00 ,  C07K2317/34 ,  C07K2319/20 ,  C07K2319/40 ,  C07K2319/74 ,  C12N2710/14143 ,  C12N2710/20022 ,  C12N2710/20023 ,  C12N2710/22022 ,  C12N2710/22023

Abstract: The invention described herein relates to compositions and methods for stimulating immune responses in vivo against a tolerogen. Novel biotechnological tools, pharmaceuticals, therapeutics and prophylactics, which concern chimeric or conjugated virus-like particles, and methods of use of the foregoing are provided for the study of B cell tolerance and the treatment or prevention of human diseases, which involve the onset of B cell tolerance, such as chronic viral infection, chronic inflammatory disease, and neoplasia.

公开(公告)号：US11633471B2

公开(公告)日：2023-04-25

申请号：US16977648

申请日：2019-03-06

Applicant: UNM Rainforest Innovations ,  The United States of America, as represented by the Secretary, Department of Health and Human Services ,  Bryce Chackerian ,  Alan Remaley ,  Marcelo Amar ,  Alexandra Fowler

Inventor： Bryce Chackerian ,  Alan Remaley ,  Marcelo Amar ,  Alexandra Fowler

IPC: A61K39/385 ,  A61K47/69 ,  A61K39/00 ,  A61K45/06 ,  C12N7/00

Abstract: An immunogen generally includes a virus-like particle and an antigen linked to the virus-like particle. The antigen includes an antigenic portion of a polypeptide, wherein the polypeptide inhibits lipoprotein lipase (LPL) activity by binding to LPL. In some embodiments, the polypeptide is at least a portion of angiopoietin-like 3 (ANGPTL3). In other embodiments, the polypeptide is at least a portion of angiopoietin-like 4 (ANGPTL4). In other embodiments, the polypeptide at least a portion of angiopoietin-like 8 (ANGPTL8). In some embodiments, the virus-like particle is a Qbeta immunogenic carrier. In some of these embodiments, the antigen is linked to the virus-like particle through a Gly-Gly-Gly-Cys linker at the C-terminal of the antigen.

公开(公告)号：US20210253641A1

公开(公告)日：2021-08-19

申请号：US17259400

申请日：2019-07-16

Applicant: Bryce Chackerian ,  Oliver Rixe ,  UNM RAINFOREST INNOVATIONS

Inventor： Bryce Chackerian ,  Oliver Rixe

IPC: C07K7/08 ,  A61K45/06 ,  C12N7/00 ,  A61K39/00

Abstract: An immunogen includes an antigenic EGFRvIII peptide linked to a Qβ bacteriophage virus-like particle (VLP) carrier. The antigenic EGFRvIII peptide has at least 53%, at least 61%, at least 69%, at least 76%, at least 84%, or at least 92% sequence similarity amino acid similarity to LEEKKGNYVVTDH (SEQ ID NO:1).

公开(公告)号：US07479280B2

公开(公告)日：2009-01-20

申请号：US11415611

申请日：2006-05-01

Applicant: John T. Schiller ,  Bryce Chackerian ,  Douglas R. Lowy

Inventor： John T. Schiller ,  Bryce Chackerian ,  Douglas R. Lowy

IPC: A61A39/00 ,  A61A39/12 ,  A61A47/48 ,  A61P29/00 ,  A61P31/12 ,  A61P31/18

CPC classification number: C12N7/00 ,  A61K38/00 ,  A61K39/00 ,  A61K47/6901 ,  A61K2039/5258 ,  C07K14/005 ,  C07K14/525 ,  C07K14/7158 ,  C07K16/084 ,  C07K16/241 ,  C07K16/2866 ,  C07K17/00 ,  C07K2317/34 ,  C07K2319/20 ,  C07K2319/40 ,  C07K2319/74 ,  C12N2710/14143 ,  C12N2710/20022 ,  C12N2710/20023 ,  C12N2710/22022 ,  C12N2710/22023

Abstract: The invention described herein relates to compositions and methods for stimulating immune responses in vivo against a tolerogen. Novel biotechnological tools, pharmaceuticals, therapeutics and prophylactics, which concern chimeric or conjugated virus-like particles, and methods of use of the foregoing are provided for the study of B cell tolerance and the treatment or prevention of human diseases, which involve the onset of B cell tolerance, such as chronic viral infection, chronic inflammatory disease, and neoplasia.